Our investment approach

In line with our proven strategy, we invest in commercially ready US and European healthcare technologies (medical devices, diagnostics and digital health) that have achieved a first regulatory approval (where relevant), are in the process of commercialisation and hold tangible intellectual property rights or entry barriers.

Candidate technologies must bring superior clinical benefits for patients over existing standard of care and/or significant efficiencies to healthcare systems and must represent a significant market opportunity.

How we help companies

Supporting our investments is as important to us as choosing them. We dedicate time to helping portfolio companies achieve their goals. We are able to support companies with their commercial and international strategies, organisational growth, manufacturing build up, clinical trials, regulatory submissions, financing, hiring and exit strategies.

Examples of support previously provided to companies

  • Introduced a company to key opinion leaders enabling them to conduct clinical trials in Europe
  • Improved and shortened a regulatory submission process to expedite CE approval
  • Recruited successful executives and independent board members
  • Proposed and managed the acquisition of key assets from a competitor for a portfolio company
  • Challenged and helped redefine the European sales strategy for a US company
  • Introduced new co-investors for a pre-IPO round

Need to know more? Take a look at our FAQ.

View Page

Testimonials

View Companies

“We are delighted to have Endeavour Vision as our partner on Willow’s mission of building solutions to moms’ most meaningful problems. They bring deep passion for our work; robust and relevant industry insights; excellent connections; and they ask outstanding, perceptive questions that help us ensure we’re thinking about and tackling the most important topics.”

Laura Chambers, CEO, Willow

“As the founding investor in CeQur, Endeavour Vision has been an invaluable partner over the years, providing strategic input, on-going support and financing. I’ve enjoyed getting to know several members of the team, each bringing their own unique expertise, and all committed to our success. In the world of healthcare technology investors, you’d be hard pressed to find a better partner.”

Bradley PaddockBradley Paddock, CEO, CeQur Corporation

“ Endeavour Vision is an extremely thorough and thoughtful healthcare investor, and at Virtual Incision we sincerely value and appreciate their Series C support. EV brings domain knowledge and a global perspective to help us pioneer the use of mini-robots for abdominal procedures — great partners to have around our board table.”

John MurphyJohn Murphy, CEO, Virtual Incision Corporation

“Endeavour Vision became our preferred partner to enter our next growth stage for a multitude of reasons. Aside from the deep level of expertise in HealthTech overall and their long-term perspective on creating sustainable change in the sector, we really valued the strong involvement of senior experts from the get go. As a result, the due diligence questions were sharp, challenging and to the point, which allowed us to dive into deep strategic conversations fast. Lastly, we simply clicked with the great team on a professional and personal level, who share the same passion to re-invent a much needed space.”

Kenbi CEOsKatrin Alberding and Clemens Raemy, Co-CEOs, Kenbi

“Endeavour Vision is a trusted and highly effective global thought partner who believes in building a company the right way. Operationally the Endeavour Vision team has broad skill sets including product development, regulatory science, clinical execution, and product launches to help achieve our mutual vision of providing a safe and effective transformational therapy that becomes the standard of care for patients worldwide.”

Dennis Wahr CEO NuvairaDennis Wahr, CEO, Nuvaira

“We find in Endeavour Vision a unique and highly-sophisticated team, which adds significant value to our commercialization ramp-up. This includes strategic input, organisational development and talent acquisition. They’re an investment team which works closely with management to identify creative solutions to complex issues, leading the maximum value creation for the enterprise. I highly recommend Endeavour Vision as a valuable venture partner.”

Earl FenderEarl R.Fender, Previously President & CEO, Vertiflex; CEO, Nalu

“As a trusted Board Member and Partner, Endeavour Vision brings a wealth of operational and financial experience to the team. They are interested in building companies the right way and creating a foundation for long-term accelerated growth, through a collaborative and detailed approach. Endeavour has always been a positive influence on our company and market. They are not only interested in representing transformational technologies but ensuring those technologies bring significant benefit to patients across the globe.”

Christopher M. OwensChristopher M. Owens, President & CEO, Gynesonics

“Endeavour Vision has been an invaluable investor in IntelyCare and a crucial partner to us in exceeding our high-growth goals and empowering healthcare heroes. Endeavour’s team has helped us identify key growth opportunities and has provided the capital needed to execute. From expanding our network of nursing professionals to building out our platform to help partnered facilities, Endeavour Vision’s leadership has been key to our rapid and sustained growth.”

David CoppinsDavid Coppins, CEO, IntelyCare

“From our introductory meeting, through the diligence and investment process and now as an active board member, the Endeavour Vision team has been a great partner. The team brings deep insights and a pragmatic approach to assisting high growth companies across a broad array of disciplines. Moreover, the team is a pleasure to work with and we look forward to our great partnership with Endeavour Vision as we continue to grow globally.”

Robert Spignesi, CEO, Rapid Micro Biosystems

“Endeavour Vision’s team brought an in-depth knowledge of our field – highlighted by impressive and thorough 360˚ due diligence, the long-term perspective required to build substantial companies, outstanding experience of bringing venture to financial success and an uncommon sense for team work. This is “smart money” at its best.”

Jaques R. Essinger, former CEO, Symetis